Business
YD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation–Driven AI Platforms for Cancer Diagnostics and Drug Development
Taipei, Taiwan, Jan. 06, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA
About this update from Yd Bio Limited
[{"type":"text","content":"Taipei, Taiwan, Jan. 06, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that the Company has entered into a Memorandum of Understanding (the “MOU”) to merge with EG BioMed, a biotechnology company specializing in DNA methylation–based cancer diagnostics and AI-driven biomarker analytics. The proposed merger represents a strategic step in building an integrated, data-driven oncology platform spanning early cancer detection, real-world clinical data generation, and AI-enabled drug discovery. The MOU is non-binding and there can be no assurance that the parties will enter into definitive agreements, obtain required approvals, or consummate the merger on the terms contemplated or on any particular timeline. Any integration benefits, including potential revenue growth, platform expansion, or cost synergies, remain subject to numerous assumptions and risks and may not be realized1. The transaction is anticipated to close in 2026, subject to customary closing conditions, regulatory approvals, and the finalization of definitive agreements. Strategic Rationale and Vision for the Future: From Single Technologies to a Platform-Based Biotech Ecosystem As precision medicine and AI-driven drug development continue to reshape the biotechnology industry, competitive advantage is increasingly defined by the ability to integrate high-quality biological data, advanced analytics, and clinical execution. The Company believes that, if completed, the merger with EG BioMed could result in the acceleration of its anticipated transition from a technology-focused company into a platform-based biotech organization anchored in clinically validated molecular data; however, expected benefits remain subject to successful execution, data generation, regulatory pathways, and market adoption, none of which can be assured. EG BioMed brings to the combined entity a robust DNA methylation diagnostics platform, AI-based biomarker algorithms, and certified clinical laboratory infrastructure, providing the Company with a critical upstream engine for both diagnostics’ commercialization and therapeutic innovation. By unifying diagnostics, therapeutics, real-world clinical data, and AI intelligence, the Co...